Tall Allen said...
halbert said...
TA, where does the "35% who retain functional erections after 2 years" come from?
I gave a link in the article. It comes from the largest, multi-institutional survey of the subject done to date, which you can read here:
Prediction of Erectile Function Following Treatment for Prostate Cancer
The study said...
The ability to attain functional erections suitable for intercourse at 2 years after treatment was reported among 177 of 511 (35% [95% CI, 30%-39%]) men who underwent prostatectomy.
The prostatectomy group included a small sample (8%) who did not have nerve sparing. The erectile function preservation among those who had nerve sparing was 37%, and was 13% among those who did not. None were on ADT.
The external beam radiotherapy group included 31% who had neoadjuvant ADT. Erectile function preservation was 44% if they did not have neoadjuvant ADT, and was 20% with it.
The brachytherapy group included 6% who had adjuvant external beam and 6% who had neoadjuvant ADT, but this did not make a statistically significant difference in erectile function at 2 years, probably owing to the small numbers who had those. Incidentally, in the Keyes et al. BT study, 44% also received six months of ADT.
I don't doubt that there are some surgeons who get better results. However, there is a lot of over-promising going on among urologists. Even with famous surgeons like Eastham and Scardino, only 43% got "back to baseline"
with ED meds, only 22% without them.
Back to Baseline: Erectile Function Recovery after Radical Prostatectomy from the Patients' Perspective- Allen
added MSKCC study
In fact, the 95% CIs from the three treatment modes (surgery, external beam, and BT) reported in JAMA are overlapping, which suggests the potential for insignificant differences...and even moreso when the potency of men following non-nerve sparing surgery results would be removed from the surgical data results.
I think it was well stated for the HW layperson a few days ago in another thread (the thread title was "Study: Surveillance Is for Middle-Risk Prostate Cancer - & more evidence of the success of LDR BT") that potency retention following all the treatment modes are probably "good, not great." In fact, "good" might be a stretch for all of them.
Allen, I believe you similarly commented on the same comparison of the same data in the recent InfoLink article on aging EF loss; you wrote: "...potency doesn’t seem to vary much between treatments in total." I see this as another way of making a very similar statement...I will encourage you, of course, to correct me if I misinterpreted your statement...
added as an edit: just to draw the complete circle, the Tall Allen InfoLink article I mentioned was, of course, the subject of the OP, the original posting of this thread...
Post Edited (NKinney) : 2/25/2015 12:00:38 PM (GMT-7)